[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Atkins KA, Jeronimo J, Stoler MH, ALTS Group: Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer; 2006 Aug 25;108(4):212-21
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study.
  • BACKGROUND: The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) accumulated information regarding conventional and liquid-based Papanicolaou (Pap) cytology, 2 kinds of human papillomavirus (HPV) DNA testing, cervicography, and colposcopically directed biopsy.
  • The prevalence of squamous cell carcinoma in these women, the efficacy of tests, and the time to detection were reviewed.
  • All results of colposcopy, HPV testing, cytology, biopsies, and cervigrams were reviewed for all women in the ALTS trial who were diagnosed with squamous cell carcinoma.
  • RESULTS: There were 7 diagnoses of invasive cancer (all squamous cell) during the 2 years of the ALTS trial.
  • Although the enrollment studies isolated many high-grade lesions, none of those results were diagnostic of the underlying carcinoma.
  • CONCLUSIONS: The prevalence of squamous cell carcinoma in the setting of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology interpretation appears to be low (approximately 1 per 1000 women in the ALTS trial).
  • Type-specific testing identified HPV type 16 in 6 of 7 cancers and HPV type 18 in 1 of 7 cancers.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16680733.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / CN-55105; United States / NCI NIH HHS / CN / CN-55152; United States / NCI NIH HHS / CN / CN-55154; United States / NCI NIH HHS / CN / CN-55155; United States / NCI NIH HHS / CN / CN-55156; United States / NCI NIH HHS / CN / CN-55157; United States / NCI NIH HHS / CN / CN-55158; United States / NCI NIH HHS / CN / CN-55159
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


2. Nahas SC, Nahas CS, Silva Filho EV, Levi JE, Atui FC, Marques CF: Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report. Sao Paulo Med J; 2007 Sep 6;125(5):292-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report.
  • CONTEXT: Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients.
  • Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
  • CASE REPORT: A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts.
  • He presented some condylomatous spreading lesions occupying part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm.
  • Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion.
  • Biopsies of the border of the perianal plaque also revealed high-grade squamous intraepithelial lesion.
  • HPV DNA testing of the anus detected the presence of HPV-16 type.
  • The patient underwent local full-thickness excision of the lesion.
  • Histological analysis on the excised tissue revealed high-grade squamous intraepithelial lesion with one focus of microinvasive squamous cell cancer measuring 1 mm.
  • The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions.
  • However no invasive squamous cell carcinoma recurrence has been detected so far.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / pathology


3. Bifulco G, Mandato VD, Piccoli R, Giampaolino P, Mignogna C, Mignogna MD, Costagliola L, Nappi C: Early invasive vulvar squamous cell carcinoma arising in a woman with vulvar pemphigus vulgaris and systemic lupus erythematosus. BMC Cancer; 2010;10:324
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early invasive vulvar squamous cell carcinoma arising in a woman with vulvar pemphigus vulgaris and systemic lupus erythematosus.
  • Systemic lupus erythematosus (SLE) is an autoimmune disease that may affect many parts of the body and the skin with occasional bullous lesions.
  • Here, we report the first case of a woman affected with SLE presenting with early invasive squamous cell carcinoma (SCC) arising from Pemphigus Vulgaris of the vulva.
  • CASE PRESENTATION: A 27-year-old Caucasian woman was admitted to our Gynaecology Unit for bleeding vegetant lesions of the vulva.
  • Biopsy showed concomitant PV and vulvar intraepithelial neoplasia (VIN) grade 3.
  • Despite chemotherapy, no remission of disease was observed.
  • Moreover, a biopsy should be always performed if there are PV lesions because of the possibility of neoplastic disease.
  • [MeSH-major] Carcinoma in Situ / etiology. Carcinoma, Squamous Cell / etiology. Lupus Erythematosus, Systemic / complications. Pemphigus / complications. Vulvar Diseases / complications. Vulvar Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Time Factors


Advertisement
4. Moodley JR, Constant D, Hoffman M, Salimo A, Allan B, Rybicki E, Hitzeroth I, Williamson AL: Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study. BMC Cancer; 2009;9:275
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study.
  • The aim of this study was to determine the prevalence of cervical squamous intraepithelial lesions (SILs), high-risk human papillomavirus (HR-HPV), HPV viral load and HPV genotypes in HIV positive women initiating anti-retroviral (ARV) therapy.
  • METHODS: A cross-sectional survey was conducted at an anti-retroviral (ARV) treatment clinic in Cape Town, SA in 2007.
  • HPV types were determined using the Roche Linear Array HPV Genotyping test.
  • Among women with abnormal smears the most prevalent HR-HPV types were HPV types 16, 58 and 51, all with a prevalence of 28.5%.
  • On univariate analysis HR-HPV, multiple HPV types and HPV viral load were significantly associated with the presence of low and high-grade SILs (LSIL/HSIL).
  • The multivariate logistic regression showed that HPV viral load was associated with an increased odds of LSIL/HSIL, odds ratio of 10.7 (95% CI 2.0 - 57.7) for those that were HC2 positive and had a viral load of <or= 181.1 RLU (the median HPV viral load), and 33.8 (95% CI 6.4 - 178.9) for those that were HC2 positive with a HPV viral load > 181.1 RLU.
  • Our results underscore the need for locally relevant, rigorous screening protocols for the increasing numbers of women accessing ARV therapy so that the benefits of ARVs are not partially offset by an excess risk in cervical cancer.
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Cervix Uteri / pathology. HIV Infections / drug therapy. Papillomavirus Infections / epidemiology. Viral Load
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active / adverse effects. Cross-Sectional Studies. Female. Humans. Middle Aged. South Africa / epidemiology. Young Adult


5. Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW: Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res; 2009 Jun 1;69(11):4750-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focal adhesion kinase (FAK), a nonreceptor protein tyrosine kinase and key modulator of integrin signaling, is widely expressed in different tissues and cell types.
  • Recent evidence indicates a central function of FAK in neoplasia where the kinase contributes to cell proliferation, resistance to apoptosis and anoikis, invasiveness, and metastasis.
  • FAK is expressed in high-grade squamous intraepithelial lesions and metastatic cervical carcinomas but not in nonneoplastic cervical mucosa.
  • In SiHa, a cervical cancer cell line with characteristics of epithelial-to-mesenchymal transition, the stable expression of dominant-negative FAK-related nonkinase decreases anchorage independence and delays xenograft growth.
  • Short-term 17-dimethylaminoethylamino-17-demethoxygeldanamycin treatment prolongs survival in a SiHa lung metastasis model and chronic administration suppresses tumor growth as well as metastatic spread in orthotopic xenografts.
  • [MeSH-major] Benzoquinones / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cell Proliferation / drug effects. Focal Adhesion Protein-Tyrosine Kinases / antagonists & inhibitors. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / therapeutic use. Protein-Tyrosine Kinases / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Disease Progression. Drug Delivery Systems / methods. Female. Gene Targeting. Genes, Dominant / physiology. Humans. Mice. Mice, SCID. Neoplasm Metastasis. Tumor Burden / drug effects. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458065.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin; EC 2.7.1.- / FAK-related nonkinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


6. Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P: Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer; 2009;9:146
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, high grade squamous intraepithelial lesion (HSIL), the precursor stage for cervical cancer, represents a growing health problem among younger women as the HSIL management regimes that have been developed are not fully effective.
  • Toxicity was monitored daily until fifteen days after the end of treatment, when patients underwent conization.
  • 75% of the patients experienced a significant lesion reduction at colposcopy and 19% exhibited full histological regression.
  • This is the first clinical trial where a drug has been used to target the CK2 phosphoaceptor domain providing an early proof-of-principle of a possible clinical benefit.
  • [MeSH-major] Casein Kinase II / antagonists & inhibitors. Cervical Intraepithelial Neoplasia / drug therapy. Drug-Related Side Effects and Adverse Reactions. Peptides, Cyclic / administration & dosage. Protein Kinase Inhibitors / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Drug Administration Routes. Drug Administration Schedule. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7127-9 [15466209.001]
  • [Cites] Cell Growth Differ. 2000 Aug;11(8):425-35 [10965847.001]
  • [Cites] J Cancer Res Clin Oncol. 1981;101(3):309-15 [6171573.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(2):161-2 [3383896.001]
  • [Cites] Obstet Gynecol. 1991 Feb;77(2):313-4 [1988900.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] Cancer Lett. 1996 Mar 19;101(1):31-5 [8625279.001]
  • [Cites] Am J Obstet Gynecol. 1996 Oct;175(4 Pt 2):1129-36 [8885798.001]
  • [Cites] J Interferon Cytokine Res. 1996 Sep;16(9):739-43 [8887059.001]
  • [Cites] J Clin Microbiol. 1997 Mar;35(3):791-5 [9041439.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):25-30 [9449906.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):391-408 [10197447.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):294-7 [15549090.001]
  • [Cites] Virology. 2005 Jan 20;331(2):269-91 [15629771.001]
  • [Cites] Anticancer Drugs. 2005 Nov;16(10):1037-43 [16222144.001]
  • [Cites] Nature. 2006 May 25;441(7092):457-62 [16724058.001]
  • [Cites] Science. 2006 May 26;312(5777):1175-8 [16728632.001]
  • [Cites] Histol Histopathol. 2001 Apr;16(2):573-82 [11332713.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):271-6 [15018855.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):169-76 [15201979.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • (PMID = 19439079.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CIGB-300; 0 / Peptides, Cyclic; 0 / Protein Kinase Inhibitors; EC 2.7.11.1 / Casein Kinase II
  • [Other-IDs] NLM/ PMC2689241
  •  go-up   go-down


7. Hubert P, Doyen J, Capelle X, Arafa M, Renoux V, Bisig B, Seidel L, Evrard B, Bousarghin L, Gerday C, Boniver J, Foidart JM, Delvenne P, Jacobs N: Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions. Am J Reprod Immunol; 2010 Aug 1;64(2):126-36
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.
  • PROBLEM: Quantitative alterations of antigen-presenting cells (APC) in (pre)neoplastic lesions of the uterine cervix associated with human papillomavirus (HPV) infection suggest a diminished capacity to capture viral antigens and to induce a protective immune response.
  • METHOD OF STUDY: To test whether a cervical application of GM-CSF could restore an immune response against HPV in women with cervical low-grade squamous intraepithelial lesions (LSIL), we performed two clinical trials with 11 healthy women and 15 patients with LSIL.
  • All the HPV16(+) patients exhibited an immune response against HPV16 after GM-CSF applications, as shown by NK and/or T cells producing IFN-gamma whereas no cellular immune response was observed before the treatment.
  • Moreover, the anti-virus-like particles antibody titers also increased after the treatment.
  • CONCLUSION: These encouraging results obtained from a limited number of subjects justify further study on the therapeutic effect of APC in cervical (pre)neoplastic lesions.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Lymphocytes, Tumor-Infiltrating / drug effects. Neoplasms, Squamous Cell / drug therapy. Papillomavirus Infections / immunology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adaptive Immunity / drug effects. Administration, Topical. Adult. Antibodies, Viral / blood. Antigen-Presenting Cells / drug effects. Antigen-Presenting Cells / immunology. Cell Line. Cell Proliferation / drug effects. Female. Human papillomavirus 16 / drug effects. Human papillomavirus 16 / immunology. Human papillomavirus 16 / isolation & purification. Humans. Immunologic Factors / administration & dosage. Immunologic Factors / adverse effects. Immunologic Factors / pharmacology. Keratinocytes / drug effects. Lymphocyte Subsets / drug effects. Lymphocyte Subsets / immunology. Middle Aged. Natural Killer T-Cells / drug effects. Natural Killer T-Cells / immunology. T-Lymphocytes, Cytotoxic / drug effects. T-Lymphocytes, Cytotoxic / immunology. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367631.001).
  • [ISSN] 1600-0897
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Immunologic Factors; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


8. Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G, Barton SE, Bower M: A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS; 2010 Sep 24;24(15):2331-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod.
  • OBJECTIVE: To determine whether imiquimod was more effective than placebo for the treatment of high-grade anal canal intraepithelial neoplasia (HG-ACIN).
  • METHODS: Sixty-four HIV-positive patients were randomized to self-application of imiquimod cream or matched placebo into the anal canal three times a week for 4 months.
  • Response was assessed by cytology, high-resolution anoscopy and biopsy 2 months after therapy.
  • All patients who failed to resolve were offered treatment with open-label imiquimod for a further 4 months.
  • RESULTS: Fifty-three patients completed the study, of which 28 patients were on active drug and 25 patients on placebo.
  • In the imiquimod group, four patients resolved and eight patients downgraded to low-grade squamous intraepithelial lesion (LSIL) with a median follow-up of 33 months.
  • Imiquimod was significantly associated with a positive outcome (P = 0.003).
  • Twenty-one patients entered a second open-label phase of treatment.
  • Five of these patients cleared their anal canal intraepithelial neoplasia (ACIN) and four patients downgraded to LSIL.
  • During this extended follow-up period, 61% have exhibited sustained absence of high-grade squamous intraepithelial lesion (HSIL).
  • CONCLUSION: This study demonstrates the effectiveness of imiquimod for the treatment of ACIN, and the benefit of prolonged or repeated treatments.
  • This form of therapy is likely to be especially valuable for patients with widespread multifocal ACIN who are otherwise difficult to treat, and should be considered as an adjunct to ablative therapy.
  • [MeSH-major] Aminoquinolines / administration & dosage. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. HIV Infections / drug therapy. HIV-1 / drug effects
  • [MeSH-minor] Administration, Cutaneous. Adult. Antiretroviral Therapy, Highly Active. Double-Blind Method. Homosexuality, Male. Humans. Male


9. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V, Bhambhani S, Roy M, Batra S, Talwar GP, Das BC: Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol; 2009 Dec;135(12):1701-9
Hazardous Substances Data Bank. QUININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions.
  • PURPOSE: 'Praneem', a polyherbal formulation developed by us, has successfully completed Phase II efficacy study for treatment of abnormal vaginal discharge due to reproductive tract infections that act as co-factors for HPV persistence.
  • In the present study we evaluated potential anti-HPV activity of Praneem in women infected with high risk HPV type 16.
  • METHODS: Twenty women molecularly diagnosed positive for HPV16 infection without or with low grade squamous intraepithelial lesion (LSIL) or inflammation were assigned to receive intra-vaginal, topical application of either Praneem tablet or placebo for 30 days excluding the days of menstrual period and were evaluated for persistence of HPV infection using HPV L1 consensus and HPV type 16-specific PCR as primary outcome.
  • RESULTS: One course of Praneem treatment resulted in elimination of HPV in 6 out of 10 (60%) cases.
  • A repeat treatment of four patients with persisting HPV infection resulted in clearance of HPV in two additional cases resulting in an overall 80% clearance of HPV 16 as against a spontaneous clearance of 10% (1/10) seen in the placebo arm.
  • CONCLUSION: Our results showed for the first time that a 30-day intra-vaginal application of the Praneem can result in elimination of HPV infection from the uterine cervix.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Human papillomavirus 16. Papillomavirus Infections / drug therapy. Plant Extracts / administration & dosage. Quinine / administration & dosage. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90 [12814991.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(2):147-50 [12701965.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Mar;5(2):149-6 [15777222.001]
  • [Cites] Indian J Exp Biol. 1996 Jul;34(7):698-701 [8979510.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2009 Feb;103(2):167-72 [18990416.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71 [7658497.001]
  • [Cites] J Ethnopharmacol. 1997 Jan;55(2):133-9 [9032626.001]
  • [Cites] Immunol Cell Biol. 1997 Apr;75(2):190-2 [9107574.001]
  • [Cites] Chembiochem. 2004 Apr 2;5(4):408-21 [15185362.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1604-13 [12419786.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1633-8 [10572150.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jul;53(7):642-50 [14985860.001]
  • [Cites] Indian J Exp Biol. 1998 Nov;36(11):1151-3 [10085786.001]
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9 [9486679.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2005 Oct;99(10):769-74 [16084547.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):409-17 [10073701.001]
  • [Cites] Am J Reprod Immunol. 2000 Mar;43(3):144-51 [10735590.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Indian J Med Res. 2006 Apr;123(4):547-52 [16783046.001]
  • [Cites] PLoS Pathog. 2006 Jul;2(7):e69 [16839203.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2006 Dec;100(12):1164-7 [16750546.001]
  • [Cites] Int J Immunopharmacol. 1992 Oct;14 (7):1187-93 [1452404.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1250-7 [17060942.001]
  • [Cites] J Med Virol. 1992 Apr;36(4):239-45 [1315836.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):951-60 [15514944.001]
  • (PMID = 19526249.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Placebos; 0 / Plant Extracts; 0 / Praneem; 0 / Vaginal Creams, Foams, and Jellies; A7V27PHC7A / Quinine
  •  go-up   go-down


10. Robinson WR, Andersen J, Darragh TM, Kendall MA, Clark R, Maiman M: Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol; 2002 May;99(5 Pt 1):777-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women.
  • OBJECTIVE: To estimate the efficacy of isotretinoin for prevention of progression of low-grade squamous intraepithelial lesions (SIL) of the cervix to high-grade lesions or invasive cervical cancer; to estimate the regression rate of low-grade SIL with isotretinoin and the toxicity of isotretinoin in this setting; and to correlate serum CD4 levels with progression of low-grade SIL.
  • METHODS: A randomized, phase III, observation-controlled, multicenter trial was performed in which 117 human immunodeficiency virus (HIV)-positive women with low-grade SIL of the cervix received either oral isotretinoin at 0.5 mg/kg per day for 6 months or observation.
  • The primary endpoint was progression to high-grade SIL or cervical cancer.
  • RESULTS: Twenty-one of 102 women (20.6%) completing follow-up experienced progression to high-grade SIL, 13 in the observation group and eight in the isotretinoin group.
  • Baseline CD4 levels were lower than anticipated (median 329 cells/mm(3)), but not associated with time to progression (P =.36).
  • Most subjects (63 of 102, 61.7%) used highly active antiretroviral therapy.
  • CONCLUSION: Isotretinoin was not associated with longer time to progression of low-grade SIL.
  • This appears to be a chronic condition in HIV-positive women, with a low risk of progression and significant rate of resolution.
  • As in the general population, observation without excisional therapy may be appropriate for HIV-positive women with low-grade SIL.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. HIV Infections / complications. Isotretinoin / therapeutic use. Uterine Cervical Neoplasms / drug therapy


11. Stanley MA: Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res; 2002 Nov;89(2):241-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and new therapeutic approaches to cervical cancer.
  • Recent advances in the detection and therapy of carcinoma of the cervix and its squamous intra-epithelial precursor lesions exploit the knowledge that these lesions are a consequence of infection with high risk (HR) human papillomavirus (HPV).
  • Detection of HR HPV DNA in smears from selected patient groups will improve detection of high grade precursor lesions and immunodetection of the cell cycle dependent kinase inhibitor p16(INK4a) seems to specifically and sensitively identify HGSIL.
  • Immunisation with HPV early proteins has been shown to have both prophylactic and therapeutic efficacy in animal papillomavirus infections and immunotherapies for low grade intra-epithelial lesions are realistic.
  • Immunotherapies for HPV associated high grade pre-cancers and invasive cancers are problematic in view of tumour immune evasion.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae / immunology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Viral Vaccines / therapeutic use
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / virology. Female. Genes, p16. Humans. Papillomavirus Infections / drug therapy. Prognosis. Tumor Virus Infections / drug therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445663.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Viral Vaccines
  •  go-up   go-down


12. Scardamaglia P, Carraro C, Mancino P, Stentella P: [Effectiveness of the treatment with beta-glucan in the HPV-CIN 1 lesions]. Minerva Ginecol; 2010 Oct;62(5):389-93
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness of the treatment with beta-glucan in the HPV-CIN 1 lesions].
  • [Transliterated title] Efficacia del carbossimetilbetaglucano nella regressione delle alterazioni citologiche cervicali di basso grado HPV correlate.
  • AIM: The aim of the study was to evaluate the effectiveness of the beta-glucan in women with abnormal cytology, including the women with a positive screening for ASCUS-LSIL furtherly divided in women with positive cytology (ASCUS or LSIL) and negative colposcopy and women with abnormal cytology, positive colposcopy and human papilloma virus (HPV)-CIN1 hystology who opted for follow-up.
  • METHODS: From September 2007 to December 2008, 60 women with ASCUS-LSIL diagnosis were recruited at the ambulatory of Lasersurgery and Cervico-Vaginal Patology, Department of Gynecology and Obstetrics of Policlinico Umberto I of Rome.
  • 1) women with cytological diagnosis of ASCUS or LSIL and negative colposcopy;.
  • All the women were treated with two cycles of a daily topical application of beta-glucan for 20 consecutive days with a suspension of 10 days.
  • The effects of beta-glucan were analyzed with colposcopy and cytology at 3.6 and 12 months from the beginning of the therapy.
  • RESULTS: After 3 months of treatment, of the 30 women with positive cytology and negative colposcopy, 80% with ASCUS diagnosis resulted negative, 35% with LSIL diagnosis resulted negative; after 6 months 100% with ASCUS diagnosis resulted negative, 70% with LSIL diagnosis resulted negative; after 12 months 85% with LSIL diagnosis resulted negative.
  • For these women the definitive treatment was the TFD.
  • CONCLUSION: Our study demonstrate the effectiveness of the treatment with beta-glucan in the women with ASCUS-LSIL lesions and HPV-CIN1 lesions, increasing of the regressions rate after 12 months of the treatment of the 15-20%.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Papillomavirus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy. beta-Glucans / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20938424.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / beta-Glucans; 61163-25-5 / carboxymethyl-beta-1,3-glucan
  •  go-up   go-down


13. González Sánchez JL, Flores Murrieta G, Chávez Brambila J, Deolarte Manzano JM, Andrade Manzano AF: [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms]. Ginecol Obstet Mex; 2002 May;70:244-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms].
  • [Transliterated title] 5-fluorouracilo tópico en el tratamiento de la neoplasia intraepitelial vaginal.
  • OBJECTIVE: Our purpose was to determine the effectiveness of 5-fluorouracil (5-FU) in the treatment of vaginal intraepithelial neoplasia (VAIN).
  • MATERIALS AND METHODS: The study was performed in 30 patients with a mean age of 54 years and previous diagnoses from reviewed records and histopathology slides selected from a group of 65 patients with VAIN from 1980 to 1998.
  • Patients received intravaginal treatment with 5-FU, 1.5 g once weekly for 10 weeks and all patients were followed up for at least 2-years.
  • RESULTS: Twenty eight (93%) patients with VAIN had prior or concurrent anogenital squamous neoplasia, including 5 with invasive cervical carcinoma and 23 with cervical intraepithelial neoplasia.
  • In 23 of 30 treated patients (77%), VAIN went into remission after a single treatment; in 3, (10%), it went into remission after two treatment; 3 (10%) had recurrent VAIN 3; and in 1 (3%) it progressed to invasive vaginal cancer.
  • The treatment was well tolerated.
  • CONCLUSIONS: The 5-FU is an option choice for VAIN treatment.
  • Its use should be confined to treating extensive or multifocal high-grade VAIN.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fluorouracil / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Papanicolaou Test. Papilloma / drug therapy. Papilloma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148464.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Caprara L, Monari F, De Bianchi PS, Amadori A, Bondi A: [ASCUS in screening]. Pathologica; 2001 Dec;93(6):645-50
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance and use of the cytological diagnosis "atypical squamous cells of undetermined significance" (ASCUS) remain a major problem in cervical cancer screening.
  • The prevalence of diagnoses of low-grade squamous intraepithelial lesions (LG-SIL) decreased progressively with age while that of high-grade SIL was slightly higher between 30 and 39 years.
  • The observed peak reflects the prevalence of (1) cytological changes closely associated with perimenopausal age and at least compatible with the ASCUS diagnosis, and (2) cytological abnormalities induced by hormone replacement therapy.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Estrogens / pharmacology. False Positive Reactions. Female. Hormone Replacement Therapy. Humans. Italy. Menopause. Middle Aged. Neoplastic Stem Cells / ultrastructure. Progesterone / pharmacology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


15. Zanoschi Ch, Anton C, Anton E, Costăchescu G, Teleman S, Costăchescu G, Ciupilan I, Cărăuleanu M, Cărăuleanu A, Leica V, Pânzaru C, Grigore M, Merticaru I, Huianu O, Huianu L, Chifan M: [Cervugid ovules in cervico-vaginal infections and cervix uteri precancerous conditions treatment]. Rev Med Chir Soc Med Nat Iasi; 2004 Jul-Sep;108(3):628-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervugid ovules in cervico-vaginal infections and cervix uteri precancerous conditions treatment].
  • This medicine was authorized by the National Drug Agency (ANM, Bucureşti) in 2001.
  • RESULTS AND DISCUSSION: Healing of the subjective symptoms in 98%, healing of the leukorrhea--as a main objective symptom--in 95%; The Bethesda system cytotest was one of the inflammatory type in the most of the cases and there wew found in 85 cases: 6 ASCUS, 41 LSIL, and 37 HSIL.
  • Cervugid may be considered as an important agent in the treatment of the precancerous affections af the cervix uteri on the following reasons: zhe cure of the infections caused by chlamydia, involved in the etiology of cervical neoplasms, the cure of the HPV infection under episome form, classified in the Bethesda system within the ASCUS, AGUS or LSIL classes.
  • In addition, it is active on chlamydia and mycoplasms, always sensitive to chloramphenicol therapy.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Chloramphenicol / therapeutic use. Hydrocortisone / analogs & derivatives. Metronidazole / therapeutic use. Nystatin / therapeutic use. Precancerous Conditions / drug therapy. Uterine Cervical Dysplasia / drug therapy. Uterine Cervicitis / drug therapy. Vaginitis / drug therapy
  • [MeSH-minor] Administration, Intravaginal. Adolescent. Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Antiprotozoal Agents / therapeutic use. Drug Combinations. Female. Humans. Middle Aged. Papanicolaou Test. Treatment Outcome. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginitis.
  • Hazardous Substances Data Bank. NYSTATIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. CHLORAMPHENICOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832988.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 0 / Antiprotozoal Agents; 0 / Cervugid; 0 / Drug Combinations; 1400-61-9 / Nystatin; 140QMO216E / Metronidazole; 3X7931PO74 / hydrocortisone acetate; 66974FR9Q1 / Chloramphenicol; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


16. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY: A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS; 2006 May 12;20(8):1151-5
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
  • OBJECTIVES: To test a therapeutic vaccine consisting of a fusion of the human papillomavirus (HPV) 16 E7 protein and the Mycobacterium bovis heat shock protein 65 (SGN-00101) to treat high-grade anal intraepithelial neoplasia (HG-AIN) in HIV-positive individuals.
  • DESIGN: A phase I/II trial with three cohorts of five participants each, sequentially assigned to receive 100, 500 or 1000 microg SGN-00101, injected three times subcutaneously in alternating thighs at 4-week intervals.
  • Anal HPV DNA was detected using L1 consensus primer-based PCR followed by type-specific probing and dot-blot hybridization (DBH).
  • HPV16, 18 and 31 DNA copy numbers were measured using quantitative real-time PCR.
  • RESULTS: There were no drug-related serious adverse events or significant changes in HIV viral load and CD4/CD8 ratio.
  • At 48 weeks, two of five participants in both the 100 and 500 microg cohorts regressed to AIN 1 and one of five participants in the 1000 microg cohort regressed to atypical squamous cells of undetermined significance (ASC-US).
  • All participants had at least one oncogenic HPV type at baseline.
  • Three of five (60%) participants who regressed to AIN 1 or ASC-US became HPV-negative using DBH and real-time PCR, compared with none of 10 participants with no clinical response (P = 0.02).
  • [MeSH-major] Anus Neoplasms / therapy. Cancer Vaccines / therapeutic use. Carcinoma in Situ / therapy. HIV Seropositivity / complications
  • [MeSH-minor] Adult. Bacterial Proteins / immunology. CD4 Lymphocyte Count. CD8-Positive T-Lymphocytes / immunology. Chaperonin 60. Chaperonins / immunology. Dose-Response Relationship, Immunologic. Female. HIV-1 / isolation & purification. Human papillomavirus 16 / immunology. Humans. Lymphocyte Count. Male. Middle Aged. Papillomaviridae / isolation & purification. Papillomavirus E7 Proteins / immunology. Papillomavirus Infections / complications. Papillomavirus Infections / therapy. Recombinant Fusion Proteins. Vaccination / methods. Viral Load. Viral Vaccines / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691066.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR 00079; United States / NCI NIH HHS / CA / U01 CA 70019; United States / NCI NIH HHS / CA / U01 CA 70047
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cancer Vaccines; 0 / Chaperonin 60; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / Viral Vaccines; 0 / heat-shock protein 65, Mycobacterium; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


17. Buxant F, Bucella D, Anaf V, Simon P, Noël JC: Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol; 2009;30(3):259-62
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix.
  • OBJECTIVES: Glucocorticoids (GCs) are used in cancer treatment to cause programmed cell death in transformed cells of the hematopoietic system and to lessen side-effects as nausea, vomiting, edema formation and allergies to specific chemotherapeutic agents.
  • Moreover, recently GCs were described as inhibitors of some chemotherapy or radiation-induced apoptosis.
  • METHODS: To clarify the issue, we tested by immunohistochemistry the expression status of GR in normal cervix epithelium (n = 30), in low-grade cervical intraepithelial neoplasia (LSIL) (n = 30), in high-grade cervical intraepithelial neoplasia (HSIL) (n = 30) and in invasive squamous cell carcinoma (ISCC) (n = 30).
  • All the patients with these lesions have a corresponding liquid-based cytology and were proved to be HPV-positive by using hybrid capture 2 methodology with probes against high-risk oncogenic HPvs. The evaluation of GR expression was performed by using the H-score system and an H-score > 50 was considered positive.
  • RESULT: GR expression was observed in normal epithelium, LSIL, HSIL and ISCC.
  • CONCLUSION: Because GCs could play a positive role in the progression of cancer, our demonstration of GR persistence in cervix cancer cells raises concern about the widespread combined use of GCs with antineoplastic drugs or agents in the clinical management of cervix cancer in women.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Receptors, Glucocorticoid / metabolism. Uterine Cervical Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697616.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid
  •  go-up   go-down


18. Berkova Z, Kaufmann RH, Unger ER, Reeves WC, Adam E: The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy. Am J Obstet Gynecol; 2003 Apr;188(4):932-7
International Agency for Research on Cancer - Screening Group. diagnostics - Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginner's Manual .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy.
  • OBJECTIVE: This study was undertaken to assess the effect of the time interval between referral cytology and the outcome of colposcopically directed biopsy in relation to human papillomavirus (HPV) DNA detected by polymerase chain reaction in women referred after abnormal Papanicolaou (Pap) smears.
  • STUDY DESIGN: The study enrolled 453 women who were referred for colposcopic examination after two Pap smears were reported as atypical squamous cells of undetermined significance (ASCUS) or low-grade intraepithelial lesions (LSIL) and 553 women who were referred with a single smear reported as high-grade squamous intraepithelial lesions (HSIL).
  • RESULTS: The results in both patient groups were evaluated in time intervals of 60 days or more, 61 to 120 days, and more than 120 days between referral and colposcopy.
  • Women of all race/ethnic backgrounds referred with HSIL were seen within 60 days in a significantly larger proportion than women referred with ASCUS/LSIL.
  • Women referred with ASCUS/LSIL had an increasing frequency of negative HPV findings with the prolonged time intervals.
  • In women referred with a single smear of HSIL, there was a significantly decreasing trend over time in detection of low-risk and unidentified types of HPV and an increasing trend of HPV DNA negative results.
  • CONCLUSION: The frequency of high-risk HPV DNA was similar in patients referred with ASCUS/LSIL or HSIL.
  • In both referral groups, there was a time-dependent increase of negative biopsy results and a decreased frequency of low-risk HPV or of unidentified HPV types.
  • This suggests that the initial abnormality on the Pap smear associated with other than high-risk HPV types may regress over time.
  • The presence of high-risk HPV DNA does not predict the actual histologically verifiable tissue changes but indicates a lower probability of negative biopsy results in all time intervals between referral and biopsy.
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Papanicolaou Test. Time Factors. Vaginal Smears

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12712088.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 200-92-0537
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


19. Klumb EM, Araújo ML Jr, Jesus GR, Santos DB, Oliveira AV, Albuquerque EM, Macedo JM: Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol; 2010 Jun;16(4):153-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?
  • RESULTS: The prevalence of atypical squamous cells of undetermined significance, low-grade and high-grade intraepithelial lesions were significantly increased in SLE patients (12.8%, 5.8%, and 3.5%, respectively) compared with controls (3.1%, 0.9%, and none, respectively, P = 0.0001), although they presented significantly fewer classic risk factors for CC.
  • SLE patients with long-term use of IM presented even higher prevalence of low-grade and high-grade intraepithelial lesions in comparison with those without long-term use of these agents (68.7% vs. 31.1%, P = 0.03).
  • CONCLUSIONS: This study provides evidence that even though not presenting the classic risk factors for CC, SLE patients, especially those exposed to long-term immunosuppression, have increased chances of presenting more premalignant lesions than the general population and they probably need to follow a more stringent CC prevention program.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Uterine Cervical Neoplasms / immunology
  • [MeSH-minor] Adult. Brazil / epidemiology. Case-Control Studies. Cross-Sectional Studies. Female. Humans. Middle Aged. Odds Ratio. Prevalence. Time Factors. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Rheumatol. 2010 Oct;16(7):355 [20921856.001]
  • (PMID = 20407390.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


20. Kiatpongsan S, Niruthisard S, Mutirangura A, Trivijitsilp P, Vasuratna A, Chaithongwongwatthana S, Lertkhachonsuk R: Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):262-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance.
  • To find the sensitivity, specificity, and positive and negative predictive values of the high-risk group human papillomavirus (HPV) DNA testing as a triage tool to detect high-grade squamous intraepithelial lesions (HSILs, ie, cervical intraepithelial neoplasia [CIN] 2 or worse) in women with a cytologic smear showing atypical squamous cells of undetermined significance (ASC-US).
  • Of the 90 ASC-US cases enrolled, the pathologic results were normal in 30.0%, squamous metaplasia in 16.7%, CIN 1 in 37.8%, CIN 2 in 1.1%, CIN 3 in 11.1%, and microinvasive cervical carcinoma in 3.3%.
  • The prevalence of HSILs and the prevalence of high-risk HPV detection were 15.6% and 38.9%, respectively.
  • High-risk group HPV detection can be used as an additional triage test to detect HSILs in women having ASC-US with high sensitivity and negative predictive value.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Cohort Studies. DNA Probes, HPV. Female. Humans. Immunohistochemistry. Middle Aged. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Risk Assessment. Sensitivity and Specificity. Thailand. Triage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445642.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


21. Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, Palefsky JM: High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis; 2004 Feb;31(2):96-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy.
  • BACKGROUND: The impact of highly active antiretroviral therapy (HAART) on the natural history of HPV infection and anal squamous intraepithelial lesions (SIL) in HIV-infected men who have sex with men (MSM) is poorly documented.
  • GOAL The goal of this study was to evaluate the prevalence of anal HPV infection and SIL inpatients under HAART.
  • Anal cytology was abnormal in 32 of 45 (71%) patients, including high-grade SIL in 10 patients (22%), low-grade SIL in 19 patients (42%), and atypical squamous cells of undetermined significance in 3 patients (7%).
  • The prevalence of anal SIL and HPV infection were similar in patients exhibiting a significant increase in CD4+ cell count after HAART initiation compared with those who did not.
  • CONCLUSION: Our results demonstrate a high prevalence of anal SIL, including high-grade SIL, and anal HPV infection in HIV-infected MSM despite immune restoration under HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / epidemiology. HIV Infections / drug therapy. Neoplasms, Squamous Cell / epidemiology. Papillomavirus Infections / epidemiology. Tumor Virus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743072.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01/101-RR-00079
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


22. Sikorski M, Zrubek H: Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection. Eur J Gynaecol Oncol; 2003;24(2):147-50
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection.
  • Human papillomavirus (HPV) proteins E6 & E7 are considered to be the constitutively expressed neoantigens in a vast majority of cervical squamous intraepithelial lesions and cancers.
  • In order to study this effect in vivo we undertook a trial in which 20 women with a definite diagnosis of cervical intraepithelial neoplasia (CIN) grade I or II with coexistent high-risk HPV infection (detected by the Hybrid Capture System) underwent four months observation followed by intracervical administration of INFgamma in cases without spontaneous regression (17 cases).
  • Human recombinant interferon gamma 1-b (Imukin) was administered intracervically four times in equal doses in two-day intervals to a total dose of 6,000,000 IU.
  • The results of therapy were verified by punch biopsy evaluation and HPV-DNA testing two months after completion, and revealed a complete response in nine women (complete regression of CIN and remission of HPV infection in 53% of treated cases) and partial response in four cases (lower grade of CIN or/and remission of HPV infection--23.5%).
  • The differences between spontaneous (before treatment) and treatment-related regressions were significant at p < 0.05.
  • We conclude that in selected cases (mainly young women who have not completed their procreation and are compliant with the therapy) a conservative approach to CIN management with intracervical IFNgamma injections seems to be a valuable method.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-gamma / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prospective Studies. Recombinant Proteins. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701965.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


23. Fusté P, Santamaría X, Carreras R: [New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy and HPV vaccines]. Med Clin (Barc); 2008 Jun 7;131(1):30-4
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy and HPV vaccines].
  • [Transliterated title] Nuevas estrategias terapéuticas para las lesiones anogenitales relacionadas con el virus del papiloma humano en pacientes con infección por el VIH: tratamiento antirretroviral de gran actividad y vacunas anti-VPH.
  • This review focuses on the recent therapeutic advances that may affect the management of neoplastic anogenital human papillomavirus (HPV)-related lesions in human immunodeficiency virus patients: highly active antiretroviral therapy (HAART) and HPV vaccines.
  • HAART shows limited benefit on the incidence of high grade intraepithelial lesions and cancer in cervix, vulva and anus.
  • On the other hand, it seems to raise discretely the spontaneous regression rates of cervical low grade lesions -cervical intraepithelial neoplasia (CIN) grade I- and condylomas, as well as the regression after treatment of CIN II-III.
  • The benefit of HAART in squamous intraepithelial lesion seems to be modest, mostly due to the improvement of the immune status.
  • HPV vaccines represent a mid-term new possibility of prevention for these lesions according to the high effectiveness shown in clinical trials, although the lack of data about effectiveness and security in HIV patients restrict its application.
  • Second generation vaccines, still to be developed, might better adapt the specific needs of these patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / complications. Anus Neoplasms / drug therapy. Genital Neoplasms, Female / complications. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Male / complications. Genital Neoplasms, Male / drug therapy. HIV Infections / complications. HIV Infections / drug therapy. Papillomavirus Infections / complications. Papillomavirus Infections / drug therapy. Papillomavirus Vaccines / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18582422.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 80
  •  go-up   go-down


24. Brändlein S, Pohle T, Vollmers C, Wozniak E, Ruoff N, Müller-Hermelink HK, Vollmers HP: CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep; 2004 Apr;11(4):777-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.
  • Furthermore, the expression of CFR-1/PAM-1 correlates with the proliferation rate and increases with the grade of malignancy.
  • Both, the unique tumor-specific expression of the CFR-1/PAM-1 receptor and the growth inhibitory effect of the PAM-1 antibody makes this combination a good diagnostic and therapeutic tool for all kinds of epithelial cancers and precursor lesions.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Apoptosis. Carcinoma / drug therapy. Receptors, Cell Surface / antagonists & inhibitors. Sialoglycoproteins / antagonists & inhibitors
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Biological Assay. Cell Line, Tumor. Humans. Immunochemistry. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Pepsin A / chemistry. Receptors, Fibroblast Growth Factor. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncol Rep. 2004 Jul;12(1):201
  • (PMID = 15010872.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / PAM-1 monoclonal antibody, human; 0 / Receptors, Cell Surface; 0 / Receptors, Fibroblast Growth Factor; 0 / Sialoglycoproteins; 0 / cysteine-rich fibroblast growth factor receptor; EC 3.4.23.1 / Pepsin A
  •  go-up   go-down


25. Joshi J, Affandi MZ, Amin P, Vaidya R, Shah R: Persistence of cytologic abnormality after treatment of bacterial, parasitic and fungal infections in older women with low grade squamous intraepithelial lesion. Acta Cytol; 2010 Mar-Apr;54(2):242-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of cytologic abnormality after treatment of bacterial, parasitic and fungal infections in older women with low grade squamous intraepithelial lesion.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Dysplasia / drug therapy. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Antiprotozoal Agents / therapeutic use. Female. Humans. Male. Middle Aged. Outcome Assessment (Health Care) / methods. Outcome Assessment (Health Care) / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391993.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Antifungal Agents; 0 / Antiprotozoal Agents
  •  go-up   go-down






Advertisement